data_2mpo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mpo _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 N--CA 1.475 0.791 0 CA-C-O 120.863 0.363 . . . . 0.0 110.768 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -81.51 64.15 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.087 0.47 . . . . 0.0 110.455 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.21 29.9 0.17 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.09 178.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -131.98 137.7 47.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.08 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 77.7 mt -56.08 100.98 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.452 0.644 . . . . 0.0 111.306 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.469 ' CG2' ' HB3' ' A' ' 167' ' ' SER . 10.7 t -105.01 145.56 13.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.068 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -58.24 114.75 2.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.494 ' HB ' HD21 ' A' ' 163' ' ' LEU . 57.9 t -80.77 127.51 74.86 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.518 -177.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.84 34.68 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.524 2.816 . . . . 0.0 113.693 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 12' ' ' SER . 9.3 m -138.31 -176.8 4.58 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 121.977 -0.452 . . . . 0.0 109.908 -178.97 -44.615 -96.134 -19.684 106.515 2.039 106.143 85.919 172.665 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -92.24 -21.56 20.27 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.602 0.715 . . . . 0.0 109.196 170.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.639 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.3 m -130.8 155.74 46.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.205 178.056 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t -84.79 145.17 8.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.545 0.212 . . . . 0.0 110.78 -174.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.466 ' HB3' ' OD1' ' A' ' 174' ' ' ASP . 82.1 m-70 -134.14 126.95 31.07 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.023 -177.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.414 ' HA ' ' HB2' ' A' ' 171' ' ' ALA . 14.0 p -130.5 150.98 35.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.41 174.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.582 ' H ' ' HB2' ' A' ' 171' ' ' ALA . 24.0 mm-40 -109.26 127.74 54.51 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 168.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -50.75 -35.62 31.24 Favored Glycine 0 C--N 1.33 0.234 0 CA-C-N 115.342 -0.845 . . . . 0.0 114.09 -174.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 23.2 t -94.61 91.04 2.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 176.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 16.5 tpt -157.74 -70.71 0.09 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.143 -176.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.542 ' HB ' ' HD2' ' A' ' 21' ' ' PRO . 69.6 p -144.88 174.79 3.17 Favored Pre-proline 0 C--N 1.327 -0.378 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.542 ' HD2' ' HB ' ' A' ' 20' ' ' THR . 5.4 Cg_exo -41.07 -29.0 0.45 Allowed 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 123.413 2.742 . . . . 0.0 113.481 167.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 67.29 62.78 0.45 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.202 0.525 . . . . 0.0 111.065 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 35.2 tt0 -43.9 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.284 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 39.7 ttm -168.86 155.57 7.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 0.0 112.389 -171.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.739 ' O ' ' HB ' ' A' ' 109' ' ' VAL . 42.8 t -105.11 156.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 113.909 -1.496 . . . . 0.0 109.077 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -154.16 105.14 2.68 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 118.618 0.645 . . . . 0.0 110.923 174.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 108' ' ' PHE . 17.7 m -111.71 134.15 55.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.82 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.628 HG22 ' SD ' ' A' ' 107' ' ' MET . 72.6 p -107.26 126.26 52.2 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.943 0.401 . . . . 0.0 111.02 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.0 -60.21 1.79 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.14 174.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 105' ' ' ALA . . . 51.54 71.64 0.43 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.065 0.46 . . . . 0.0 111.846 177.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 158' ' ' VAL . . . 115.94 114.83 2.89 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.402 ' CB ' HG21 ' A' ' 158' ' ' VAL . 2.8 p90 -133.51 -176.93 4.32 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 176.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.476 ' N ' ' HA3' ' A' ' 157' ' ' GLY . 30.2 t70 -104.38 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.479 176.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.612 ' O ' ' HB ' ' A' ' 66' ' ' ILE . 32.0 p-10 -118.43 -30.2 5.27 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.276 0.56 . . . . 0.0 110.466 175.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.553 ' O ' ' HB1' ' A' ' 155' ' ' ALA . . . 112.38 -112.8 3.11 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.109 174.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.581 ' HA ' ' O ' ' A' ' 61' ' ' CYS . 3.5 p 38.45 66.81 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-O 122.405 1.098 . . . . 0.0 110.574 -174.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . 0.581 ' HG ' ' CE2' ' A' ' 106' ' ' PHE . 2.3 mm? -57.64 124.89 20.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.165 -1.38 . . . . 0.0 110.196 -178.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -120.67 103.14 8.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.178 0.513 . . . . 0.0 110.452 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.561 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 65.3 t80 -94.06 153.1 18.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.434 177.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -156.41 151.36 26.18 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.019 0.438 . . . . 0.0 111.307 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 7.9 p -126.93 150.09 32.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 175.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.574 ' O ' HD23 ' A' ' 149' ' ' LEU . 1.8 p -111.86 178.22 4.39 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.508 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 50.7 ttt-85 -149.32 146.8 21.75 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.75 175.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 43' ' ' ARG . 95.6 Cg_endo -79.1 153.6 24.99 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.443 2.096 . . . . 0.0 112.576 176.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.77 -34.79 26.97 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.708 174.104 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 44' ' ' PRO . 40.3 mtpt -122.47 154.38 37.88 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.334 175.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.5 p -88.61 75.61 8.26 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.139 0.495 . . . . 0.0 112.292 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 123.49 -19.96 7.48 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.861 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.86 -111.77 3.49 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.38 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -64.58 104.05 0.75 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.933 0.397 . . . . 0.0 110.108 177.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.4 HG23 ' CB ' ' A' ' 44' ' ' PRO . 42.3 p -112.51 93.01 4.23 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.568 -175.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.6 m -153.97 52.74 0.69 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.545 ' HG3' ' H ' ' A' ' 54' ' ' SER . 25.1 tpt180 -85.81 178.27 7.37 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 174.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.545 ' H ' ' HG3' ' A' ' 53' ' ' ARG . 3.4 p -63.81 163.03 12.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.407 0.622 . . . . 0.0 112.49 -176.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' HIS . . . . . 0.405 ' O ' ' HB2' ' A' ' 82' ' ' PHE . 19.2 m170 -75.47 107.48 7.63 Favored 'General case' 0 C--O 1.219 -0.505 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.481 HD13 ' HB ' ' A' ' 143' ' ' VAL . 0.4 OUTLIER -66.82 -27.25 67.41 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -164.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.466 ' HB3' HG13 ' A' ' 143' ' ' VAL . . . -155.19 149.15 25.65 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.524 -178.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.481 ' OG ' ' HB3' ' A' ' 80' ' ' LYS . 27.3 p -142.78 147.61 35.81 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.577 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.809 HG23 ' SG ' ' A' ' 77' ' ' CYS . 12.6 mt -131.97 106.42 11.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' MET . . . . . 0.557 ' HA ' ' O ' ' A' ' 37' ' ' LEU . 52.7 ttp -104.02 124.61 49.34 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.455 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.581 ' O ' ' HA ' ' A' ' 36' ' ' VAL . 68.5 m -106.18 135.38 47.76 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.074 0.464 . . . . 0.0 110.236 -178.224 -58.184 -15.765 -88.252 105.466 2.029 104.349 109.805 -146.027 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.451 ' HH ' ' HB2' ' A' ' 78' ' ' PHE . 0.0 OUTLIER -105.78 116.49 32.03 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.45 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.41 ' O ' HG22 ' A' ' 69' ' ' VAL . 8.0 t -109.08 173.96 6.08 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -177.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -95.38 30.48 2.22 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.887 0.851 . . . . 0.0 109.151 -176.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -118.35 -47.92 2.54 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.911 178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.612 ' HB ' ' O ' ' A' ' 34' ' ' ASN . 0.0 OUTLIER -69.62 132.42 33.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.205 175.169 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -81.1 134.1 35.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 107.15 18.29 10.62 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.549 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.451 ' CG1' HG22 ' A' ' 66' ' ' ILE . 16.2 m -93.8 154.62 40.89 Favored Pre-proline 0 C--N 1.32 -0.685 0 CA-C-O 120.734 0.302 . . . . 0.0 110.873 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.08 121.5 9.89 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.989 1.792 . . . . 0.0 110.788 173.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -70.02 -17.3 63.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.336 0.589 . . . . 0.0 110.397 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.03 -24.73 30.36 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.941 178.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.437 ' HD2' ' OE1' ' A' ' 94' ' ' GLU . 45.5 mtpt -127.22 14.56 7.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -174.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.33 114.31 3.41 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.114 0.483 . . . . 0.0 110.069 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.621 ' O ' ' HA ' ' A' ' 98' ' ' PRO . . . 111.06 20.47 7.13 Favored Glycine 0 N--CA 1.433 -1.503 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.82 -175.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.544 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 74.3 mmtt -129.88 177.85 6.96 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' CYS . . . . . 0.809 ' SG ' HG23 ' A' ' 59' ' ' ILE . 0.9 OUTLIER -135.67 153.56 51.57 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.93 0.395 . . . . 0.0 110.37 179.594 -146.027 109.805 -88.252 104.349 2.029 105.466 -15.765 -58.184 3 3 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.451 ' HB2' ' HH ' ' A' ' 62' ' ' TYR . 2.3 t80 -117.76 139.53 50.93 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -178.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.45 HD23 ' CG2' ' A' ' 95' ' ' VAL . 3.0 pp -101.81 138.14 39.19 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.591 -0.444 . . . . 0.0 109.887 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.497 ' HD2' ' HG3' ' A' ' 92' ' ' GLU . 2.0 tttm -126.81 142.26 51.59 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.055 174.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . 0.677 ' ND2' HG12 ' A' ' 143' ' ' VAL . 5.6 t-20 -124.22 140.97 52.45 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.456 -0.793 . . . . 0.0 108.896 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.462 ' HA ' HD12 ' A' ' 90' ' ' ILE . 18.8 m-85 -112.01 144.96 40.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.139 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.602 ' HA ' ' OG ' ' A' ' 87' ' ' SER . 40.5 t -59.15 84.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 O-C-N 123.981 0.801 . . . . 0.0 111.863 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.582 ' H ' ' HB3' ' A' ' 87' ' ' SER . . . -104.08 -131.56 7.23 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.78 170.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -69.78 -62.17 1.49 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -173.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.61 26.71 4.8 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.736 0.779 . . . . 0.0 110.771 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' SER . . . . . 0.602 ' OG ' ' HA ' ' A' ' 83' ' ' SER . 36.7 t -112.24 -78.82 0.58 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.645 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . 0.547 ' HA ' ' OG ' ' A' ' 83' ' ' SER . 20.8 t 58.29 20.94 7.7 Favored 'General case' 0 CA--C 1.538 0.509 0 O-C-N 123.509 0.505 . . . . 0.0 110.71 -174.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -178.69 136.58 0.15 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.169 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.462 HD12 ' HA ' ' A' ' 82' ' ' PHE . 23.5 mm -63.79 123.65 16.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 174.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -115.16 122.11 45.05 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.497 ' HG3' ' HD2' ' A' ' 80' ' ' LYS . 2.8 mt-10 -121.2 123.71 42.92 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.207 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.402 ' O ' ' HG ' ' A' ' 79' ' ' LEU . 25.5 mmtp -139.03 130.66 27.36 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.629 0.728 . . . . 0.0 112.079 -178.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.437 ' OE1' ' HD2' ' A' ' 73' ' ' LYS . 24.6 tt0 -74.3 138.91 43.86 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.421 171.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.67 ' HB ' ' CD2' ' A' ' 97' ' ' LEU . 1.7 t -136.72 160.56 37.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.46 -178.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.4 m -85.15 88.55 7.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.864 -179.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.67 ' CD2' ' HB ' ' A' ' 95' ' ' VAL . 2.6 mm? -125.48 100.56 31.82 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 175.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.621 ' HA ' ' O ' ' A' ' 75' ' ' GLY . 43.7 Cg_endo -71.29 117.74 5.31 Favored 'Trans proline' 0 CA--C 1.534 0.497 0 C-N-CA 121.698 1.599 . . . . 0.0 113.224 -178.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.458 HD12 ' C ' ' A' ' 98' ' ' PRO . 4.3 mp -138.48 82.86 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 171.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.487 ' HZ1' ' HB3' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -150.31 81.35 1.36 Allowed 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -175.522 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.443 ' CB ' ' HA ' ' A' ' 126' ' ' ASP . 65.1 p -147.81 -16.58 0.36 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -174.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 60.0 m80 62.01 17.2 8.82 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 120.687 0.28 . . . . 0.0 110.707 -175.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.421 ' C ' ' H ' ' A' ' 105' ' ' ALA . 7.0 t30 -82.39 -11.25 58.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.241 -172.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . 0.425 ' HB3' ' HA2' ' A' ' 31' ' ' GLY . 3.1 m-20 71.63 -27.85 0.18 Allowed 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.524 ' HA ' ' HA ' ' A' ' 30' ' ' ALA . . . -80.81 124.72 29.31 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.411 0.624 . . . . 0.0 111.32 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' PHE . . . . . 0.581 ' CE2' ' HG ' ' A' ' 37' ' ' LEU . 65.6 t80 -156.48 152.39 27.33 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.763 -174.149 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.628 ' SD ' HG22 ' A' ' 28' ' ' THR . 58.9 mtm -143.16 143.89 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.12 0.485 . . . . 0.0 111.116 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.561 ' CD2' ' HB2' ' A' ' 39' ' ' PHE . 0.3 OUTLIER -117.78 118.3 31.67 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.832 175.02 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.739 ' HB ' ' O ' ' A' ' 25' ' ' VAL . 0.9 OUTLIER -123.23 148.29 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.245 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' CYS . . . . . 0.584 ' HA ' ' HA ' ' A' ' 120' ' ' CYS . 95.1 m -145.64 143.18 29.68 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.767 0.318 . . . . 0.0 110.951 -178.786 -66.118 -92.109 102.876 104.971 2.032 103.678 -88.857 -68.081 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.8 p -130.67 142.69 50.44 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.095 0.474 . . . . 0.0 111.512 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.3 p -123.4 89.3 3.07 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 172.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -74.77 -36.95 62.55 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.291 -169.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -95.87 -15.28 22.55 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.285 -176.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 83.33 2.35 90.3 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.076 179.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 64.7 m -132.01 17.69 4.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.343 0.592 . . . . 0.0 109.974 176.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -156.07 148.6 23.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.79 179.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 13.7 tp -123.67 124.29 42.43 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.392 0.615 . . . . 0.0 110.343 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -118.35 151.61 37.4 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 175.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.584 ' HA ' ' HA ' ' A' ' 110' ' ' CYS . 88.9 m -127.64 147.94 50.37 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.401 -178.93 -68.081 -88.857 102.876 103.678 2.032 104.971 -92.109 -66.118 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.591 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . 8.2 m-20 -117.83 115.53 25.15 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 173.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.42 ' CG2' ' HG ' ' A' ' 97' ' ' LEU . 33.3 t -87.89 111.77 22.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.599 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.636 ' HA ' ' O ' ' A' ' 135' ' ' LYS . 28.2 m-85 -96.05 137.73 34.7 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.611 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.446 ' HB1' ' HD2' ' A' ' 135' ' ' LYS . . . -151.63 139.68 20.12 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -93.26 110.95 22.47 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . 0.566 ' OD1' HG22 ' A' ' 128' ' ' THR . 11.1 t70 -92.74 149.91 21.0 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 176.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -76.18 -22.02 55.81 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.607 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' THR . . . . . 0.566 HG22 ' OD1' ' A' ' 126' ' ' ASP . 5.4 t -91.32 -19.67 22.7 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 175.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.51 ' HB2' ' HB3' ' A' ' 126' ' ' ASP . 94.1 m-20 -101.38 13.21 35.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.596 178.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 19.1 p -62.81 -29.08 70.44 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.726 -174.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 7.5 m -70.66 -31.15 67.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.962 0.41 . . . . 0.0 110.655 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -89.01 -25.46 21.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.369 0.604 . . . . 0.0 110.072 177.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 101.62 -140.2 14.76 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.71 -0.677 . . . . 0.0 112.112 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.407 ' CD2' ' HE2' ' A' ' 107' ' ' MET . 21.2 m95 -75.8 148.0 38.77 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.11 0.481 . . . . 0.0 110.931 -177.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.636 ' O ' ' HA ' ' A' ' 123' ' ' PHE . 0.0 OUTLIER -93.89 149.24 21.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.418 173.737 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.47 ' C ' HD21 ' A' ' 137' ' ' ASN . 7.5 p -133.5 118.4 30.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.254 0.55 . . . . 0.0 110.984 -179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.47 HD21 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -130.55 133.5 46.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.654 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' THR . . . . . . . . . . . . . 24.6 m -87.35 141.15 28.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.181 0.515 . . . . 0.0 111.407 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.5 122.64 35.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 173.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -87.83 123.44 32.61 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.423 ' HG ' ' HB1' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -84.11 -27.9 27.86 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.948 0.404 . . . . 0.0 111.662 -173.988 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 76.64 9.8 86.1 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.097 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.677 HG12 ' ND2' ' A' ' 81' ' ' ASN . 17.0 m -101.11 151.81 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 33.8 p -107.39 157.94 17.57 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.643 0.259 . . . . 0.0 110.782 -177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 m -95.79 163.73 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.029 0.442 . . . . 0.0 110.812 -175.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.602 ' H ' ' HG ' ' A' ' 149' ' ' LEU . 69.9 m -153.69 171.72 6.59 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 -173.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.86 0.2 0.11 Allowed 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 124.412 3.408 . . . . 0.0 116.318 -175.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ASP . . . . . 0.484 ' O ' ' HD3' ' A' ' 44' ' ' PRO . 18.7 t70 -157.21 92.51 1.25 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.378 0.608 . . . . 0.0 109.555 176.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . 0.602 ' HG ' ' H ' ' A' ' 146' ' ' SER . 0.3 OUTLIER -122.58 31.2 6.18 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.548 -166.672 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -58.14 137.34 57.05 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.605 0.716 . . . . 0.0 111.568 -169.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -106.67 171.24 7.47 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.537 -1.211 . . . . 0.0 110.455 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.26 147.7 6.82 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.718 -0.754 . . . . 0.0 111.923 173.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.38 125.68 51.4 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 173.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 9.5 t -125.31 146.62 49.48 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.104 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ALA . . . . . 0.553 ' HB1' ' O ' ' A' ' 35' ' ' GLY . . . -164.87 148.92 8.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.433 ' HB2' ' OD1' ' A' ' 34' ' ' ASN . 6.2 m-20 -66.76 114.31 5.54 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.319 0.58 . . . . 0.0 110.611 -178.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.476 ' HA3' ' N ' ' A' ' 33' ' ' ASP . . . 98.85 -15.64 60.51 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.157 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.547 ' CG2' ' HB2' ' A' ' 155' ' ' ALA . 2.9 t -76.43 123.85 33.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.9 0.381 . . . . 0.0 110.498 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -119.61 115.2 23.5 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 14.2 t -69.75 97.87 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.067 0.461 . . . . 0.0 110.759 -176.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -71.05 -37.11 72.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.84 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.499 ' HB3' ' CE2' ' A' ' 164' ' ' TYR . 98.6 mttt -134.41 137.4 44.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.274 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.639 HD23 ' C ' ' A' ' 12' ' ' SER . 11.3 tp -128.63 116.58 19.82 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -177.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' TYR . . . . . 0.499 ' CE2' ' HB3' ' A' ' 162' ' ' LYS . 68.6 m-85 -125.98 146.17 49.99 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.634 0.731 . . . . 0.0 112.26 -174.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.406 ' HB2' HG22 ' A' ' 170' ' ' THR . . . -155.3 156.53 35.69 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.775 -1.102 . . . . 0.0 108.252 172.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 42.6 t -57.74 135.41 56.77 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' SER . . . . . 0.469 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.0 p -59.29 -16.13 19.98 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -176.037 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.03 -21.7 48.7 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.187 172.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' LEU . . . . . 0.411 ' HG ' HG21 ' A' ' 15' ' ' VAL . 9.7 tt -96.41 -14.24 22.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.476 -0.362 . . . . 0.0 110.148 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.449 HG22 HG22 ' A' ' 8' ' ' VAL . 32.0 p -74.79 55.93 0.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.136 0.493 . . . . 0.0 110.988 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ALA . . . . . 0.582 ' HB2' ' H ' ' A' ' 16' ' ' GLN . . . -89.81 94.92 10.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.715 -178.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 23.7 mm -91.01 85.0 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.28 -175.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -127.13 30.36 5.44 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.612 0.72 . . . . 0.0 109.233 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.466 ' OD1' ' HB3' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -102.71 -174.44 2.56 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.003 -173.427 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -92.74 140.35 23.72 Favored Pre-proline 0 C--N 1.324 -0.541 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.547 173.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -63.21 -5.95 8.96 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 123.016 2.477 . . . . 0.0 112.799 -179.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 27.5 t -69.86 -17.67 63.38 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.041 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' LEU . . . . . . . . . . . . . 35.9 mt -86.55 27.33 0.97 Allowed 'General case' 0 CA--C 1.512 -0.502 0 CA-C-O 120.732 0.301 . . . . 0.0 111.271 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' GLY . . . . . . . . . . . . . . . 58.98 75.45 0.27 Allowed Glycine 0 N--CA 1.444 -0.811 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' CYS . . . . . 0.462 ' HB2' ' HB3' ' A' ' 10' ' ' CYS . 29.3 t -155.94 137.6 14.2 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 122.388 -0.477 . . . . 0.0 111.369 -176.556 172.665 85.919 -19.684 106.143 2.039 106.515 -96.134 -44.615 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 63.8 tttm -90.07 117.98 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.839 177.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.66 -0.686 . . . . 0.0 110.923 -176.815 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 N--CA 1.475 0.791 0 CA-C-O 120.863 0.363 . . . . 0.0 110.768 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -81.51 64.15 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.087 0.47 . . . . 0.0 110.455 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.21 29.9 0.17 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.09 178.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -131.98 137.7 47.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.08 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 77.7 mt -56.08 100.98 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.452 0.644 . . . . 0.0 111.306 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' CG2' ' HB3' ' A' ' 167' ' ' SER . 10.7 t -105.01 145.56 13.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.068 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -58.24 114.75 2.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.525 HG22 HG22 ' A' ' 170' ' ' THR . 57.9 t -80.77 127.51 74.86 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.518 -177.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.84 34.68 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.524 2.816 . . . . 0.0 113.693 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB2' ' O ' ' A' ' 12' ' ' SER . 9.3 m -138.31 -176.8 4.58 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 121.977 -0.452 . . . . 0.0 109.908 -178.97 -44.615 -96.134 -19.684 106.515 2.039 106.143 85.919 172.665 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -92.24 -21.56 20.27 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.602 0.715 . . . . 0.0 109.196 170.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.623 ' C ' HD21 ' A' ' 163' ' ' LEU . 4.3 m -130.8 155.74 46.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.205 178.056 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 25' ' ' VAL . 69.4 t -84.79 145.17 8.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.545 0.212 . . . . 0.0 110.78 -174.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.474 ' HB3' ' OD1' ' A' ' 174' ' ' ASP . 82.1 m-70 -134.14 126.95 31.07 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.023 -177.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.511 ' HA ' ' HB3' ' A' ' 171' ' ' ALA . 14.0 p -130.5 150.98 35.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.41 174.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.612 ' H ' ' HB3' ' A' ' 171' ' ' ALA . 24.0 mm-40 -109.26 127.74 54.51 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 168.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.492 ' N ' ' HA ' ' A' ' 147' ' ' PRO . . . -50.75 -35.62 31.24 Favored Glycine 0 C--N 1.33 0.234 0 CA-C-N 115.342 -0.845 . . . . 0.0 114.09 -174.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 23.2 t -94.61 91.04 2.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 176.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 16.5 tpt -157.74 -70.71 0.09 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.143 -176.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.551 ' HB ' ' HD2' ' A' ' 21' ' ' PRO . 69.6 p -144.88 174.79 3.17 Favored Pre-proline 0 C--N 1.327 -0.378 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.551 ' HD2' ' HB ' ' A' ' 20' ' ' THR . 5.4 Cg_exo -41.07 -29.0 0.45 Allowed 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 123.413 2.742 . . . . 0.0 113.481 167.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 67.29 62.78 0.45 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.202 0.525 . . . . 0.0 111.065 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 35.2 tt0 -43.9 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.284 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 39.7 ttm -168.86 155.57 7.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 0.0 112.389 -171.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.754 ' O ' ' HB ' ' A' ' 109' ' ' VAL . 42.8 t -105.11 156.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 113.909 -1.496 . . . . 0.0 109.077 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -154.16 105.14 2.68 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 118.618 0.645 . . . . 0.0 110.923 174.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 108' ' ' PHE . 17.7 m -111.71 134.15 55.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.82 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.64 HG22 ' SD ' ' A' ' 107' ' ' MET . 72.6 p -107.26 126.26 52.2 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.943 0.401 . . . . 0.0 111.02 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.0 -60.21 1.79 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.14 174.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 105' ' ' ALA . . . 51.54 71.64 0.43 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.065 0.46 . . . . 0.0 111.846 177.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 158' ' ' VAL . . . 115.94 114.83 2.89 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.451 ' CB ' HG23 ' A' ' 158' ' ' VAL . 2.8 p90 -133.51 -176.93 4.32 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 176.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.478 ' N ' ' HA3' ' A' ' 157' ' ' GLY . 30.2 t70 -104.38 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.479 176.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.608 ' O ' ' HB ' ' A' ' 66' ' ' ILE . 32.0 p-10 -118.43 -30.2 5.27 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.276 0.56 . . . . 0.0 110.466 175.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 155' ' ' ALA . . . 112.38 -112.8 3.11 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.109 174.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.587 ' HA ' ' O ' ' A' ' 61' ' ' CYS . 3.5 p 38.45 66.81 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-O 122.405 1.098 . . . . 0.0 110.574 -174.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.639 ' H ' HD22 ' A' ' 37' ' ' LEU . 2.3 mm? -57.64 124.89 20.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.165 -1.38 . . . . 0.0 110.196 -178.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -120.67 103.14 8.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.178 0.513 . . . . 0.0 110.452 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 65.3 t80 -94.06 153.1 18.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.434 177.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -156.41 151.36 26.18 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.019 0.438 . . . . 0.0 111.307 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 7.9 p -126.93 150.09 32.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 175.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.557 ' O ' HD22 ' A' ' 149' ' ' LEU . 1.8 p -111.86 178.22 4.39 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.515 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 50.7 ttt-85 -149.32 146.8 21.75 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.75 175.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HD2' ' CG ' ' A' ' 43' ' ' ARG . 95.6 Cg_endo -79.1 153.6 24.99 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.443 2.096 . . . . 0.0 112.576 176.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.77 -34.79 26.97 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.708 174.104 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.493 ' O ' ' HB2' ' A' ' 44' ' ' PRO . 40.3 mtpt -122.47 154.38 37.88 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.334 175.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.5 p -88.61 75.61 8.26 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.139 0.495 . . . . 0.0 112.292 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 123.49 -19.96 7.48 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.861 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.86 -111.77 3.49 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.38 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -64.58 104.05 0.75 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.933 0.397 . . . . 0.0 110.108 177.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.462 HG22 ' CB ' ' A' ' 44' ' ' PRO . 42.3 p -112.51 93.01 4.23 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.568 -175.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.6 m -153.97 52.74 0.69 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.542 ' HG3' ' H ' ' A' ' 54' ' ' SER . 25.1 tpt180 -85.81 178.27 7.37 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 174.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.542 ' H ' ' HG3' ' A' ' 53' ' ' ARG . 3.4 p -63.81 163.03 12.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.407 0.622 . . . . 0.0 112.49 -176.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' HIS . . . . . 0.401 ' O ' ' HB2' ' A' ' 82' ' ' PHE . 0.4 OUTLIER -75.47 107.48 7.63 Favored 'General case' 0 C--O 1.219 -0.505 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.258 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.577 HD21 ' HA3' ' A' ' 84' ' ' GLY . 0.4 OUTLIER -66.82 -27.25 67.41 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -164.966 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.634 ' HB2' HG11 ' A' ' 143' ' ' VAL . . . -155.19 149.15 25.65 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.524 -178.048 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.491 ' OG ' ' HB3' ' A' ' 80' ' ' LYS . 27.3 p -142.78 147.61 35.81 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.577 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.813 HG22 ' SG ' ' A' ' 77' ' ' CYS . 12.6 mt -131.97 106.42 11.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' MET . . . . . 0.565 ' HA ' ' O ' ' A' ' 37' ' ' LEU . 52.7 ttp -104.02 124.61 49.34 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.455 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 36' ' ' VAL . 68.5 m -106.18 135.38 47.76 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.074 0.464 . . . . 0.0 110.236 -178.224 -58.184 -15.765 -88.252 105.466 2.029 104.349 109.805 -146.027 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.418 ' CE2' ' HE2' ' A' ' 73' ' ' LYS . 0.0 OUTLIER -105.78 116.49 32.03 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.45 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.413 ' O ' HG21 ' A' ' 69' ' ' VAL . 8.0 t -109.08 173.96 6.08 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -177.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -95.38 30.48 2.22 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.887 0.851 . . . . 0.0 109.151 -176.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -118.35 -47.92 2.54 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.911 178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.608 ' HB ' ' O ' ' A' ' 34' ' ' ASN . 0.0 OUTLIER -69.62 132.42 33.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.205 175.169 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -81.1 134.1 35.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 107.15 18.29 10.62 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.549 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.474 ' CG1' HG23 ' A' ' 66' ' ' ILE . 16.2 m -93.8 154.62 40.89 Favored Pre-proline 0 C--N 1.32 -0.685 0 CA-C-O 120.734 0.302 . . . . 0.0 110.873 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.08 121.5 9.89 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.989 1.792 . . . . 0.0 110.788 173.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -70.02 -17.3 63.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.336 0.589 . . . . 0.0 110.397 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.03 -24.73 30.36 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.941 178.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.422 ' HD2' ' OE1' ' A' ' 94' ' ' GLU . 45.5 mtpt -127.22 14.56 7.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -174.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.33 114.31 3.41 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.114 0.483 . . . . 0.0 110.069 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.68 ' O ' ' HA ' ' A' ' 98' ' ' PRO . . . 111.06 20.47 7.13 Favored Glycine 0 N--CA 1.433 -1.503 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.82 -175.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 74.3 mmtt -129.88 177.85 6.96 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' CYS . . . . . 0.813 ' SG ' HG22 ' A' ' 59' ' ' ILE . 0.9 OUTLIER -135.67 153.56 51.57 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.93 0.395 . . . . 0.0 110.37 179.594 -146.027 109.805 -88.252 104.349 2.029 105.466 -15.765 -58.184 3 3 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -117.76 139.53 50.93 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -178.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.456 HD23 ' CG2' ' A' ' 95' ' ' VAL . 3.0 pp -101.81 138.14 39.19 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.591 -0.444 . . . . 0.0 109.887 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.513 ' HD2' ' HG3' ' A' ' 92' ' ' GLU . 2.0 tttm -126.81 142.26 51.59 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.055 174.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASN . . . . . 0.582 ' ND2' HG12 ' A' ' 143' ' ' VAL . 5.6 t-20 -124.22 140.97 52.45 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.456 -0.793 . . . . 0.0 108.896 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.531 ' HA ' HD13 ' A' ' 90' ' ' ILE . 18.8 m-85 -112.01 144.96 40.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.139 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.597 ' HA ' ' OG ' ' A' ' 87' ' ' SER . 40.5 t -59.15 84.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 O-C-N 123.981 0.801 . . . . 0.0 111.863 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.658 ' H ' ' HB3' ' A' ' 87' ' ' SER . . . -104.08 -131.56 7.23 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.78 170.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -69.78 -62.17 1.49 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -173.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.61 26.71 4.8 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.736 0.779 . . . . 0.0 110.771 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' SER . . . . . 0.658 ' HB3' ' H ' ' A' ' 84' ' ' GLY . 36.7 t -112.24 -78.82 0.58 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.645 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.543 ' HA ' ' OG ' ' A' ' 83' ' ' SER . 20.8 t 58.29 20.94 7.7 Favored 'General case' 0 CA--C 1.538 0.509 0 O-C-N 123.509 0.505 . . . . 0.0 110.71 -174.518 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -178.69 136.58 0.15 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.169 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.531 HD13 ' HA ' ' A' ' 82' ' ' PHE . 23.5 mm -63.79 123.65 16.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 174.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -115.16 122.11 45.05 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.513 ' HG3' ' HD2' ' A' ' 80' ' ' LYS . 2.8 mt-10 -121.2 123.71 42.92 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.207 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.414 ' O ' ' HG ' ' A' ' 79' ' ' LEU . 25.5 mmtp -139.03 130.66 27.36 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.629 0.728 . . . . 0.0 112.079 -178.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.422 ' OE1' ' HD2' ' A' ' 73' ' ' LYS . 24.6 tt0 -74.3 138.91 43.86 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.421 171.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.678 ' HB ' ' CD2' ' A' ' 97' ' ' LEU . 1.7 t -136.72 160.56 37.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.46 -178.067 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.4 m -85.15 88.55 7.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.864 -179.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.678 ' CD2' ' HB ' ' A' ' 95' ' ' VAL . 2.6 mm? -125.48 100.56 31.82 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 175.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.68 ' HA ' ' O ' ' A' ' 75' ' ' GLY . 43.7 Cg_endo -71.29 117.74 5.31 Favored 'Trans proline' 0 CA--C 1.534 0.497 0 C-N-CA 121.698 1.599 . . . . 0.0 113.224 -178.366 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.46 HD12 ' C ' ' A' ' 98' ' ' PRO . 4.3 mp -138.48 82.86 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 171.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.471 ' NZ ' ' HB3' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -150.31 81.35 1.36 Allowed 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -175.522 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.456 ' CB ' ' HA ' ' A' ' 126' ' ' ASP . 65.1 p -147.81 -16.58 0.36 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -174.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 60.0 m80 62.01 17.2 8.82 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 120.687 0.28 . . . . 0.0 110.707 -175.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 104' ' ' ASP . 11.4 t-20 -82.39 -11.25 58.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.241 -172.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.427 ' HB3' ' HA2' ' A' ' 31' ' ' GLY . 3.1 m-20 71.63 -27.85 0.18 Allowed 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' ALA . . . -80.81 124.72 29.31 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.411 0.624 . . . . 0.0 111.32 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' PHE . . . . . 0.597 ' CE2' ' HG ' ' A' ' 37' ' ' LEU . 65.6 t80 -156.48 152.39 27.33 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.763 -174.149 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.64 ' SD ' HG22 ' A' ' 28' ' ' THR . 58.9 mtm -143.16 143.89 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.12 0.485 . . . . 0.0 111.116 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 39' ' ' PHE . 0.3 OUTLIER -117.78 118.3 31.67 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.832 175.02 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.754 ' HB ' ' O ' ' A' ' 25' ' ' VAL . 0.9 OUTLIER -123.23 148.29 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.245 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' CYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 120' ' ' CYS . 95.1 m -145.64 143.18 29.68 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.767 0.318 . . . . 0.0 110.951 -178.786 -66.118 -92.109 102.876 104.971 2.032 103.678 -88.857 -68.081 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.8 p -130.67 142.69 50.44 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.095 0.474 . . . . 0.0 111.512 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.3 p -123.4 89.3 3.07 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 172.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -74.77 -36.95 62.55 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.291 -169.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.446 ' OD1' ' HB3' ' A' ' 117' ' ' ALA . 8.1 p-10 -95.87 -15.28 22.55 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.285 -176.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.405 ' O ' HG22 ' A' ' 145' ' ' VAL . . . 83.33 2.35 90.3 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.076 179.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 64.7 m -132.01 17.69 4.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.343 0.592 . . . . 0.0 109.974 176.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ALA . . . . . 0.446 ' HB3' ' OD1' ' A' ' 114' ' ' ASP . . . -156.07 148.6 23.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.79 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 13.7 tp -123.67 124.29 42.43 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.392 0.615 . . . . 0.0 110.343 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -118.35 151.61 37.4 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 175.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 110' ' ' CYS . 88.9 m -127.64 147.94 50.37 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.401 -178.93 -68.081 -88.857 102.876 103.678 2.032 104.971 -92.109 -66.118 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.607 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . 8.2 m-20 -117.83 115.53 25.15 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 173.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.643 HG21 ' HG ' ' A' ' 97' ' ' LEU . 33.3 t -87.89 111.77 22.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.599 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.645 ' HA ' ' O ' ' A' ' 135' ' ' LYS . 28.2 m-85 -96.05 137.73 34.7 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.611 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.503 ' HB3' ' HD2' ' A' ' 135' ' ' LYS . . . -151.63 139.68 20.12 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -93.26 110.95 22.47 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' A' ' 128' ' ' THR . 11.1 t70 -92.74 149.91 21.0 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 176.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -76.18 -22.02 55.81 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.607 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' THR . . . . . 0.572 HG22 ' OD1' ' A' ' 126' ' ' ASP . 5.4 t -91.32 -19.67 22.7 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 175.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ASN . . . . . 0.526 ' HB2' ' HB3' ' A' ' 126' ' ' ASP . 94.1 m-20 -101.38 13.21 35.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.596 178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 19.1 p -62.81 -29.08 70.44 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.726 -174.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 7.5 m -70.66 -31.15 67.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.962 0.41 . . . . 0.0 110.655 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -89.01 -25.46 21.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.369 0.604 . . . . 0.0 110.072 177.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 101.62 -140.2 14.76 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.71 -0.677 . . . . 0.0 112.112 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -75.8 148.0 38.77 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.11 0.481 . . . . 0.0 110.931 -177.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.645 ' O ' ' HA ' ' A' ' 123' ' ' PHE . 0.0 OUTLIER -93.89 149.24 21.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.418 173.737 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.5 118.4 30.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.254 0.55 . . . . 0.0 110.984 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 7.9 m-20 -130.55 133.5 46.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' THR . . . . . . . . . . . . . 24.6 m -87.35 141.15 28.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.181 0.515 . . . . 0.0 111.407 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.5 122.64 35.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 173.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -87.83 123.44 32.61 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.544 ' HB3' HG22 ' A' ' 143' ' ' VAL . 0.2 OUTLIER -84.11 -27.9 27.86 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.948 0.404 . . . . 0.0 111.662 -173.988 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 76.64 9.8 86.1 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.097 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 57' ' ' ALA . 17.0 m -101.11 151.81 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 33.8 p -107.39 157.94 17.57 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.643 0.259 . . . . 0.0 110.782 -177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.542 ' HA ' HD11 ' A' ' 149' ' ' LEU . 2.6 m -95.79 163.73 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.029 0.442 . . . . 0.0 110.812 -175.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.593 ' H ' ' HG ' ' A' ' 149' ' ' LEU . 69.9 m -153.69 171.72 6.59 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 -173.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.492 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 72.3 Cg_exo -54.86 0.2 0.11 Allowed 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 124.412 3.408 . . . . 0.0 116.318 -175.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ASP . . . . . 0.496 ' O ' ' HD3' ' A' ' 44' ' ' PRO . 18.7 t70 -157.21 92.51 1.25 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.378 0.608 . . . . 0.0 109.555 176.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' LEU . . . . . 0.593 ' HG ' ' H ' ' A' ' 146' ' ' SER . 0.3 OUTLIER -122.58 31.2 6.18 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.548 -166.672 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -58.14 137.34 57.05 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.605 0.716 . . . . 0.0 111.568 -169.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -106.67 171.24 7.47 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.537 -1.211 . . . . 0.0 110.455 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.26 147.7 6.82 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.718 -0.754 . . . . 0.0 111.923 173.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.38 125.68 51.4 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 173.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 9.5 t -125.31 146.62 49.48 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.104 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ALA . . . . . 0.55 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . . . -164.87 148.92 8.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.454 ' HB2' ' OD1' ' A' ' 34' ' ' ASN . 6.2 m-20 -66.76 114.31 5.54 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.319 0.58 . . . . 0.0 110.611 -178.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.478 ' HA3' ' N ' ' A' ' 33' ' ' ASP . . . 98.85 -15.64 60.51 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.157 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.55 ' CG2' ' HB3' ' A' ' 155' ' ' ALA . 2.9 t -76.43 123.85 33.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.9 0.381 . . . . 0.0 110.498 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -119.61 115.2 23.5 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.482 HG11 HD13 ' A' ' 163' ' ' LEU . 14.2 t -69.75 97.87 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.067 0.461 . . . . 0.0 110.759 -176.234 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -71.05 -37.11 72.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.84 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.511 ' HB3' ' CE2' ' A' ' 164' ' ' TYR . 98.6 mttt -134.41 137.4 44.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.274 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.623 HD21 ' C ' ' A' ' 12' ' ' SER . 11.3 tp -128.63 116.58 19.82 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -177.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' TYR . . . . . 0.511 ' CE2' ' HB3' ' A' ' 162' ' ' LYS . 68.6 m-85 -125.98 146.17 49.99 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.634 0.731 . . . . 0.0 112.26 -174.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.499 ' HB1' HD22 ' A' ' 169' ' ' LEU . . . -155.3 156.53 35.69 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.775 -1.102 . . . . 0.0 108.252 172.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 42.6 t -57.74 135.41 56.77 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.474 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.0 p -59.29 -16.13 19.98 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -176.037 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.03 -21.7 48.7 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.187 172.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' LEU . . . . . 0.499 HD22 ' HB1' ' A' ' 165' ' ' ALA . 9.7 tt -96.41 -14.24 22.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.476 -0.362 . . . . 0.0 110.148 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.525 HG22 HG22 ' A' ' 8' ' ' VAL . 32.0 p -74.79 55.93 0.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.136 0.493 . . . . 0.0 110.988 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ALA . . . . . 0.612 ' HB3' ' H ' ' A' ' 16' ' ' GLN . . . -89.81 94.92 10.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.715 -178.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 23.7 mm -91.01 85.0 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.28 -175.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -127.13 30.36 5.44 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.612 0.72 . . . . 0.0 109.233 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -102.71 -174.44 2.56 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.003 -173.427 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -92.74 140.35 23.72 Favored Pre-proline 0 C--N 1.324 -0.541 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.547 173.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -63.21 -5.95 8.96 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 123.016 2.477 . . . . 0.0 112.799 -179.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 27.5 t -69.86 -17.67 63.38 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.041 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' LEU . . . . . . . . . . . . . 35.9 mt -86.55 27.33 0.97 Allowed 'General case' 0 CA--C 1.512 -0.502 0 CA-C-O 120.732 0.301 . . . . 0.0 111.271 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' GLY . . . . . . . . . . . . . . . 58.98 75.45 0.27 Allowed Glycine 0 N--CA 1.444 -0.811 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' CYS . . . . . 0.445 ' HB2' ' HB3' ' A' ' 10' ' ' CYS . 29.3 t -155.94 137.6 14.2 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 122.388 -0.477 . . . . 0.0 111.369 -176.556 172.665 85.919 -19.684 106.143 2.039 106.515 -96.134 -44.615 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 63.8 tttm -90.07 117.98 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.839 177.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.66 -0.686 . . . . 0.0 110.923 -176.815 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.6 p . . . . . 0 N--CA 1.475 0.791 0 CA-C-O 120.863 0.363 . . . . 0.0 110.768 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -81.51 64.15 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.087 0.47 . . . . 0.0 110.455 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.21 29.9 0.17 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.09 178.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -131.98 137.7 47.99 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.08 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 77.7 mt -56.08 100.98 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.452 0.644 . . . . 0.0 111.306 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' CG2' ' HB3' ' A' ' 167' ' ' SER . 10.7 t -105.01 145.56 13.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.068 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -58.24 114.75 2.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.525 HG22 HG22 ' A' ' 170' ' ' THR . 57.9 t -80.77 127.51 74.86 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.518 -177.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.84 34.68 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.524 2.816 . . . . 0.0 113.693 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB2' ' O ' ' A' ' 12' ' ' SER . 9.3 m -138.31 -176.8 4.58 Favored 'General case' 0 C--N 1.32 -0.683 0 O-C-N 121.977 -0.452 . . . . 0.0 109.908 -178.97 -44.615 -96.134 -19.684 106.515 2.039 106.143 85.919 172.665 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -92.24 -21.56 20.27 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.602 0.715 . . . . 0.0 109.196 170.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.623 ' C ' HD21 ' A' ' 163' ' ' LEU . 4.3 m -130.8 155.74 46.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.205 178.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 25' ' ' VAL . 69.4 t -84.79 145.17 8.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.545 0.212 . . . . 0.0 110.78 -174.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.474 ' HB3' ' OD1' ' A' ' 174' ' ' ASP . 82.1 m-70 -134.14 126.95 31.07 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.023 -177.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.511 ' HA ' ' HB3' ' A' ' 171' ' ' ALA . 14.0 p -130.5 150.98 35.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.41 174.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.612 ' H ' ' HB3' ' A' ' 171' ' ' ALA . 24.0 mm-40 -109.26 127.74 54.51 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 168.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.492 ' N ' ' HA ' ' A' ' 147' ' ' PRO . . . -50.75 -35.62 31.24 Favored Glycine 0 C--N 1.33 0.234 0 CA-C-N 115.342 -0.845 . . . . 0.0 114.09 -174.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 23.2 t -94.61 91.04 2.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 176.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 16.5 tpt -157.74 -70.71 0.09 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.143 -176.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.551 ' HB ' ' HD2' ' A' ' 21' ' ' PRO . 69.6 p -144.88 174.79 3.17 Favored Pre-proline 0 C--N 1.327 -0.378 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.551 ' HD2' ' HB ' ' A' ' 20' ' ' THR . 5.4 Cg_exo -41.07 -29.0 0.45 Allowed 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 123.413 2.742 . . . . 0.0 113.481 167.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 67.29 62.78 0.45 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.202 0.525 . . . . 0.0 111.065 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 35.2 tt0 -43.9 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.284 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 39.7 ttm -168.86 155.57 7.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 0.0 112.389 -171.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.754 ' O ' ' HB ' ' A' ' 109' ' ' VAL . 42.8 t -105.11 156.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 113.909 -1.496 . . . . 0.0 109.077 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -154.16 105.14 2.68 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 118.618 0.645 . . . . 0.0 110.923 174.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 108' ' ' PHE . 17.7 m -111.71 134.15 55.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.82 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.64 HG22 ' SD ' ' A' ' 107' ' ' MET . 72.6 p -107.26 126.26 52.2 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.943 0.401 . . . . 0.0 111.02 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.0 -60.21 1.79 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.14 174.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 105' ' ' ALA . . . 51.54 71.64 0.43 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.065 0.46 . . . . 0.0 111.846 177.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 158' ' ' VAL . . . 115.94 114.83 2.89 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.451 ' CB ' HG23 ' A' ' 158' ' ' VAL . 2.8 p90 -133.51 -176.93 4.32 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 176.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.478 ' N ' ' HA3' ' A' ' 157' ' ' GLY . 30.2 t70 -104.38 -56.4 2.19 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.479 176.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.608 ' O ' ' HB ' ' A' ' 66' ' ' ILE . 32.0 p-10 -118.43 -30.2 5.27 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.276 0.56 . . . . 0.0 110.466 175.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 155' ' ' ALA . . . 112.38 -112.8 3.11 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.109 174.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.587 ' HA ' ' O ' ' A' ' 61' ' ' CYS . 3.5 p 38.45 66.81 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-O 122.405 1.098 . . . . 0.0 110.574 -174.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.639 ' H ' HD22 ' A' ' 37' ' ' LEU . 2.3 mm? -57.64 124.89 20.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.165 -1.38 . . . . 0.0 110.196 -178.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -120.67 103.14 8.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.178 0.513 . . . . 0.0 110.452 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 65.3 t80 -94.06 153.1 18.32 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.434 177.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -156.41 151.36 26.18 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.019 0.438 . . . . 0.0 111.307 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 7.9 p -126.93 150.09 32.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 175.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.557 ' O ' HD22 ' A' ' 149' ' ' LEU . 1.8 p -111.86 178.22 4.39 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.515 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 50.7 ttt-85 -149.32 146.8 21.75 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.75 175.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HD2' ' CG ' ' A' ' 43' ' ' ARG . 95.6 Cg_endo -79.1 153.6 24.99 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.443 2.096 . . . . 0.0 112.576 176.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.77 -34.79 26.97 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.708 174.104 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.493 ' O ' ' HB2' ' A' ' 44' ' ' PRO . 40.3 mtpt -122.47 154.38 37.88 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.334 175.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.5 p -88.61 75.61 8.26 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.139 0.495 . . . . 0.0 112.292 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 123.49 -19.96 7.48 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.861 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.86 -111.77 3.49 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.38 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -64.58 104.05 0.75 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.933 0.397 . . . . 0.0 110.108 177.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.462 HG22 ' CB ' ' A' ' 44' ' ' PRO . 42.3 p -112.51 93.01 4.23 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.568 -175.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.6 m -153.97 52.74 0.69 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.542 ' HG3' ' H ' ' A' ' 54' ' ' SER . 25.1 tpt180 -85.81 178.27 7.37 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 174.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.542 ' H ' ' HG3' ' A' ' 53' ' ' ARG . 3.4 p -63.81 163.03 12.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.407 0.622 . . . . 0.0 112.49 -176.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' HIS . . . . . 0.401 ' O ' ' HB2' ' A' ' 82' ' ' PHE . 19.2 m170 -75.47 107.48 7.63 Favored 'General case' 0 C--O 1.219 -0.505 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.577 HD21 ' HA3' ' A' ' 84' ' ' GLY . 0.4 OUTLIER -66.82 -27.25 67.41 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -164.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.634 ' HB2' HG11 ' A' ' 143' ' ' VAL . . . -155.19 149.15 25.65 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.891 -0.324 . . . . 0.0 110.524 -178.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.491 ' OG ' ' HB3' ' A' ' 80' ' ' LYS . 27.3 p -142.78 147.61 35.81 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.577 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.813 HG22 ' SG ' ' A' ' 77' ' ' CYS . 12.6 mt -131.97 106.42 11.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . 0.565 ' HA ' ' O ' ' A' ' 37' ' ' LEU . 52.7 ttp -104.02 124.61 49.34 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.455 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 36' ' ' VAL . 68.5 m -106.18 135.38 47.76 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.074 0.464 . . . . 0.0 110.236 -178.224 -58.184 -15.765 -88.252 105.466 2.029 104.349 109.805 -146.027 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.418 ' CE2' ' HE2' ' A' ' 73' ' ' LYS . 0.0 OUTLIER -105.78 116.49 32.03 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.45 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.413 ' O ' HG21 ' A' ' 69' ' ' VAL . 8.0 t -109.08 173.96 6.08 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -177.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -95.38 30.48 2.22 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.887 0.851 . . . . 0.0 109.151 -176.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -118.35 -47.92 2.54 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.911 178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.608 ' HB ' ' O ' ' A' ' 34' ' ' ASN . 0.0 OUTLIER -69.62 132.42 33.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.205 175.169 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -81.1 134.1 35.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 107.15 18.29 10.62 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.549 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.474 ' CG1' HG23 ' A' ' 66' ' ' ILE . 16.2 m -93.8 154.62 40.89 Favored Pre-proline 0 C--N 1.32 -0.685 0 CA-C-O 120.734 0.302 . . . . 0.0 110.873 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.08 121.5 9.89 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.989 1.792 . . . . 0.0 110.788 173.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -70.02 -17.3 63.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.336 0.589 . . . . 0.0 110.397 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.03 -24.73 30.36 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.941 178.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.422 ' HD2' ' OE1' ' A' ' 94' ' ' GLU . 45.5 mtpt -127.22 14.56 7.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -174.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.33 114.31 3.41 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.114 0.483 . . . . 0.0 110.069 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.68 ' O ' ' HA ' ' A' ' 98' ' ' PRO . . . 111.06 20.47 7.13 Favored Glycine 0 N--CA 1.433 -1.503 0 C-N-CA 120.643 -0.789 . . . . 0.0 111.82 -175.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 74.3 mmtt -129.88 177.85 6.96 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' CYS . . . . . 0.813 ' SG ' HG22 ' A' ' 59' ' ' ILE . 0.9 OUTLIER -135.67 153.56 51.57 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.93 0.395 . . . . 0.0 110.37 179.594 -146.027 109.805 -88.252 104.349 2.029 105.466 -15.765 -58.184 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -117.76 139.53 50.93 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -178.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.456 HD23 ' CG2' ' A' ' 95' ' ' VAL . 3.0 pp -101.81 138.14 39.19 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.591 -0.444 . . . . 0.0 109.887 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.513 ' HD2' ' HG3' ' A' ' 92' ' ' GLU . 2.0 tttm -126.81 142.26 51.59 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.055 174.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . 0.582 ' ND2' HG12 ' A' ' 143' ' ' VAL . 5.6 t-20 -124.22 140.97 52.45 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.456 -0.793 . . . . 0.0 108.896 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.531 ' HA ' HD13 ' A' ' 90' ' ' ILE . 18.8 m-85 -112.01 144.96 40.51 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.139 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.597 ' HA ' ' OG ' ' A' ' 87' ' ' SER . 40.5 t -59.15 84.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 O-C-N 123.981 0.801 . . . . 0.0 111.863 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.658 ' H ' ' HB3' ' A' ' 87' ' ' SER . . . -104.08 -131.56 7.23 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.78 170.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -69.78 -62.17 1.49 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -173.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.61 26.71 4.8 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.736 0.779 . . . . 0.0 110.771 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . 0.658 ' HB3' ' H ' ' A' ' 84' ' ' GLY . 36.7 t -112.24 -78.82 0.58 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.645 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . 0.543 ' HA ' ' OG ' ' A' ' 83' ' ' SER . 20.8 t 58.29 20.94 7.7 Favored 'General case' 0 CA--C 1.538 0.509 0 O-C-N 123.509 0.505 . . . . 0.0 110.71 -174.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -178.69 136.58 0.15 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.169 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.531 HD13 ' HA ' ' A' ' 82' ' ' PHE . 23.5 mm -63.79 123.65 16.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 174.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -115.16 122.11 45.05 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.513 ' HG3' ' HD2' ' A' ' 80' ' ' LYS . 2.8 mt-10 -121.2 123.71 42.92 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.207 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.414 ' O ' ' HG ' ' A' ' 79' ' ' LEU . 25.5 mmtp -139.03 130.66 27.36 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.629 0.728 . . . . 0.0 112.079 -178.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.422 ' OE1' ' HD2' ' A' ' 73' ' ' LYS . 24.6 tt0 -74.3 138.91 43.86 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.421 171.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.678 ' HB ' ' CD2' ' A' ' 97' ' ' LEU . 1.7 t -136.72 160.56 37.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.46 -178.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.4 m -85.15 88.55 7.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.864 -179.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.678 ' CD2' ' HB ' ' A' ' 95' ' ' VAL . 2.6 mm? -125.48 100.56 31.82 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 175.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.68 ' HA ' ' O ' ' A' ' 75' ' ' GLY . 43.7 Cg_endo -71.29 117.74 5.31 Favored 'Trans proline' 0 CA--C 1.534 0.497 0 C-N-CA 121.698 1.599 . . . . 0.0 113.224 -178.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.46 HD12 ' C ' ' A' ' 98' ' ' PRO . 4.3 mp -138.48 82.86 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 171.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.471 ' NZ ' ' HB3' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -150.31 81.35 1.36 Allowed 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -175.522 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.456 ' CB ' ' HA ' ' A' ' 126' ' ' ASP . 65.1 p -147.81 -16.58 0.36 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -174.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 60.0 m80 62.01 17.2 8.82 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 120.687 0.28 . . . . 0.0 110.707 -175.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 104' ' ' ASP . 7.0 t30 -82.39 -11.25 58.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.241 -172.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.427 ' HB3' ' HA2' ' A' ' 31' ' ' GLY . 3.1 m-20 71.63 -27.85 0.18 Allowed 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 178.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' ALA . . . -80.81 124.72 29.31 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.411 0.624 . . . . 0.0 111.32 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' PHE . . . . . 0.597 ' CE2' ' HG ' ' A' ' 37' ' ' LEU . 65.6 t80 -156.48 152.39 27.33 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.763 -174.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.64 ' SD ' HG22 ' A' ' 28' ' ' THR . 58.9 mtm -143.16 143.89 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.12 0.485 . . . . 0.0 111.116 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 39' ' ' PHE . 0.3 OUTLIER -117.78 118.3 31.67 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.832 175.02 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.754 ' HB ' ' O ' ' A' ' 25' ' ' VAL . 0.9 OUTLIER -123.23 148.29 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 179.245 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' CYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 120' ' ' CYS . 95.1 m -145.64 143.18 29.68 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.767 0.318 . . . . 0.0 110.951 -178.786 -66.118 -92.109 102.876 104.971 2.032 103.678 -88.857 -68.081 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.8 p -130.67 142.69 50.44 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.095 0.474 . . . . 0.0 111.512 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 49.3 p -123.4 89.3 3.07 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 172.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -74.77 -36.95 62.55 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.291 -169.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.446 ' OD1' ' HB3' ' A' ' 117' ' ' ALA . 8.1 p-10 -95.87 -15.28 22.55 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.285 -176.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.405 ' O ' HG22 ' A' ' 145' ' ' VAL . . . 83.33 2.35 90.3 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.995 -0.621 . . . . 0.0 113.076 179.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 64.7 m -132.01 17.69 4.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.343 0.592 . . . . 0.0 109.974 176.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . 0.446 ' HB3' ' OD1' ' A' ' 114' ' ' ASP . . . -156.07 148.6 23.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.79 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 13.7 tp -123.67 124.29 42.43 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.392 0.615 . . . . 0.0 110.343 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -118.35 151.61 37.4 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 175.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' HA ' ' A' ' 110' ' ' CYS . 88.9 m -127.64 147.94 50.37 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.401 -178.93 -68.081 -88.857 102.876 103.678 2.032 104.971 -92.109 -66.118 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.607 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . 8.2 m-20 -117.83 115.53 25.15 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 173.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.643 HG21 ' HG ' ' A' ' 97' ' ' LEU . 33.3 t -87.89 111.77 22.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.599 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.645 ' HA ' ' O ' ' A' ' 135' ' ' LYS . 28.2 m-85 -96.05 137.73 34.7 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.611 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.503 ' HB3' ' HD2' ' A' ' 135' ' ' LYS . . . -151.63 139.68 20.12 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -93.26 110.95 22.47 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' A' ' 128' ' ' THR . 11.1 t70 -92.74 149.91 21.0 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 176.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -76.18 -22.02 55.81 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.607 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . 0.572 HG22 ' OD1' ' A' ' 126' ' ' ASP . 5.4 t -91.32 -19.67 22.7 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 175.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . 0.526 ' HB2' ' HB3' ' A' ' 126' ' ' ASP . 94.1 m-20 -101.38 13.21 35.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.596 178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 19.1 p -62.81 -29.08 70.44 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.726 -174.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 7.5 m -70.66 -31.15 67.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.962 0.41 . . . . 0.0 110.655 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -89.01 -25.46 21.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.369 0.604 . . . . 0.0 110.072 177.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 101.62 -140.2 14.76 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 115.71 -0.677 . . . . 0.0 112.112 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -75.8 148.0 38.77 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.11 0.481 . . . . 0.0 110.931 -177.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.645 ' O ' ' HA ' ' A' ' 123' ' ' PHE . 0.0 OUTLIER -93.89 149.24 21.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.418 173.737 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.499 ' C ' HD22 ' A' ' 137' ' ' ASN . 7.5 p -133.5 118.4 30.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.254 0.55 . . . . 0.0 110.984 -179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.499 HD22 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -130.55 133.5 46.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.654 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' THR . . . . . . . . . . . . . 24.6 m -87.35 141.15 28.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.181 0.515 . . . . 0.0 111.407 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.5 122.64 35.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.862 173.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -87.83 123.44 32.61 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.544 ' HB3' HG22 ' A' ' 143' ' ' VAL . 0.2 OUTLIER -84.11 -27.9 27.86 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.948 0.404 . . . . 0.0 111.662 -173.988 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 76.64 9.8 86.1 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.097 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 57' ' ' ALA . 17.0 m -101.11 151.81 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 33.8 p -107.39 157.94 17.57 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.643 0.259 . . . . 0.0 110.782 -177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.542 ' HA ' HD11 ' A' ' 149' ' ' LEU . 2.6 m -95.79 163.73 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.029 0.442 . . . . 0.0 110.812 -175.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.593 ' H ' ' HG ' ' A' ' 149' ' ' LEU . 69.9 m -153.69 171.72 6.59 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 -173.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.492 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 72.3 Cg_exo -54.86 0.2 0.11 Allowed 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 124.412 3.408 . . . . 0.0 116.318 -175.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ASP . . . . . 0.496 ' O ' ' HD3' ' A' ' 44' ' ' PRO . 18.7 t70 -157.21 92.51 1.25 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.378 0.608 . . . . 0.0 109.555 176.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . 0.593 ' HG ' ' H ' ' A' ' 146' ' ' SER . 0.3 OUTLIER -122.58 31.2 6.18 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.548 -166.672 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -58.14 137.34 57.05 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.605 0.716 . . . . 0.0 111.568 -169.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -106.67 171.24 7.47 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.537 -1.211 . . . . 0.0 110.455 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.26 147.7 6.82 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.718 -0.754 . . . . 0.0 111.923 173.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.38 125.68 51.4 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 173.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 9.5 t -125.31 146.62 49.48 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.104 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ALA . . . . . 0.55 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . . . -164.87 148.92 8.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.454 ' HB2' ' OD1' ' A' ' 34' ' ' ASN . 6.2 m-20 -66.76 114.31 5.54 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.319 0.58 . . . . 0.0 110.611 -178.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.478 ' HA3' ' N ' ' A' ' 33' ' ' ASP . . . 98.85 -15.64 60.51 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.157 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.55 ' CG2' ' HB3' ' A' ' 155' ' ' ALA . 2.9 t -76.43 123.85 33.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.9 0.381 . . . . 0.0 110.498 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -119.61 115.2 23.5 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.482 HG11 HD13 ' A' ' 163' ' ' LEU . 14.2 t -69.75 97.87 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.067 0.461 . . . . 0.0 110.759 -176.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -71.05 -37.11 72.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.84 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.511 ' HB3' ' CE2' ' A' ' 164' ' ' TYR . 98.6 mttt -134.41 137.4 44.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.274 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.623 HD21 ' C ' ' A' ' 12' ' ' SER . 11.3 tp -128.63 116.58 19.82 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -177.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' TYR . . . . . 0.511 ' CE2' ' HB3' ' A' ' 162' ' ' LYS . 68.6 m-85 -125.98 146.17 49.99 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.634 0.731 . . . . 0.0 112.26 -174.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.499 ' HB1' HD22 ' A' ' 169' ' ' LEU . . . -155.3 156.53 35.69 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 114.775 -1.102 . . . . 0.0 108.252 172.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 42.6 t -57.74 135.41 56.77 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.474 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.0 p -59.29 -16.13 19.98 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -176.037 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.03 -21.7 48.7 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.187 172.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' LEU . . . . . 0.499 HD22 ' HB1' ' A' ' 165' ' ' ALA . 9.7 tt -96.41 -14.24 22.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.476 -0.362 . . . . 0.0 110.148 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.525 HG22 HG22 ' A' ' 8' ' ' VAL . 32.0 p -74.79 55.93 0.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.136 0.493 . . . . 0.0 110.988 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ALA . . . . . 0.612 ' HB3' ' H ' ' A' ' 16' ' ' GLN . . . -89.81 94.92 10.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.715 -178.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 23.7 mm -91.01 85.0 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.28 -175.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -127.13 30.36 5.44 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.612 0.72 . . . . 0.0 109.233 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -102.71 -174.44 2.56 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.003 -173.427 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -92.74 140.35 23.72 Favored Pre-proline 0 C--N 1.324 -0.541 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.547 173.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -63.21 -5.95 8.96 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 123.016 2.477 . . . . 0.0 112.799 -179.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 27.5 t -69.86 -17.67 63.38 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.041 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' LEU . . . . . . . . . . . . . 35.9 mt -86.55 27.33 0.97 Allowed 'General case' 0 CA--C 1.512 -0.502 0 CA-C-O 120.732 0.301 . . . . 0.0 111.271 177.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' GLY . . . . . . . . . . . . . . . 58.98 75.45 0.27 Allowed Glycine 0 N--CA 1.444 -0.811 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' CYS . . . . . 0.445 ' HB2' ' HB3' ' A' ' 10' ' ' CYS . 29.3 t -155.94 137.6 14.2 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 122.388 -0.477 . . . . 0.0 111.369 -176.556 172.665 85.919 -19.684 106.143 2.039 106.515 -96.134 -44.615 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 63.8 tttm -90.07 117.98 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.839 177.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.66 -0.686 . . . . 0.0 110.923 -176.815 . . . . . . . . 0 0 . 1 stop_ save_